- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03408262
Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women (Ad4HIV)
A Phase I Single-Blind Randomised Trial Investigating Immunisation Strategies Using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA Combinations in Order to Maximise Antibody Responses to Human Immunodeficiency Virus
This is a randomised two-part Phase I study which will explore the impact of different boosting options (MVA-CN54 and recombinant CN54gp140 protein) for oral Adenovirus serotype 4 vector prime expressing HIV-1 CN54 envelope (Ad4-EnvCN54) designed to optimize systemic and mucosal antibody responses.
Part 1 is exploratory and designed to select conditions capable of promoting enhanced systemic and mucosal B cell responses in a limited number of participants. Part 2 is dependent upon Part 1 and is designed to study groups selected on performance in part 1 in an expanded number of subjects. Data from both stages will be combined for safety and immunological analyses.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W12 0HS
- NIHR Imperial Clinical Research Facility
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged between 18 and 50 years on the day of screening
- BMI between 18-30
- Seronegative for Adenovirus 4 serum neutralising antibodies
- Available for follow-up for the duration of the study
- Willing and able to give written informed consent
At low risk of HIV infection and willing to remain so for the duration of the study defined as:
- no history of injecting drug use in the previous ten years
- no gonorrhoea or syphilis in the last six months
- no high risk partner (e.g. injecting drug use, HIV positive partner) either currently or within the past six months
- no unprotected anal or vaginal intercourse in the last six months, outside a relationship with a regular partner known to be HIV negative
- Willing to undergo HIV testing
- Willing to undergo a STI screen for chlamydia, gonorrhoea and syphilis
- Must agree to require male sexual partner to use condoms, from at least 14 days before the first vaccination until at least 4 months after the last
- If heterosexually active female capable of becoming pregnant, must (in addition to requiring male partner to use condoms) agree to use hormonal contraception, or to complete abstinence, from at least 30 days before the first vaccination until at least 4 months after the last. [Note: Acceptable hormonal contraception is combined (estrogen and progestogen containing) or progestogen-only hormonal contraception associated with inhibition of ovulation. Complete abstinence can be used, when in line with the preferred and usual lifestyle of the subject. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, lactational amenorrhoea method, and IUD/IUS are not acceptable methods of contraception.]
- If sexually active male, must agree to use condoms from the day of first vaccination until at least 4 months after the last. [Note: Additional use of an effective method of contraception is recommended for any non-pregnant female partner over the same period.]
- Agree to abstain from donating blood, eggs or sperm from the day of first vaccination until at least 3 months after the end of their participation in the trial
- Registered with a GP for at least the past month
- Entered and clearance obtained from The Overvolunteering Prevention System (TOPS) database
Exclusion Criteria:
- Are pregnant or breast feeding, or living with anyone under the age of 5 years old or over 75 years old
- Have close contact with an immunocompromised individual thought to be at clinical risk from Adenovirus infection
Clinically relevant abnormality on history or examination including:
- Liver disease with inadequate hepatic function
- Any skin condition which may interfere with the trial assessment of the injection sites
- Haematological, metabolic, gastrointestinal or cardio-pulmonary disorders
- Uncontrolled infection; autoimmune disease, immunodeficiency
- Known hypersensitivity to any component of the vaccine formulations used in this trial, or have severe or multiple allergies to drugs or pharmaceutical agents
History of severe local or general reaction to vaccination defined as
- Local: extensive, indurated redness and swelling involving most of the antero-lateral thigh or the arm, not resolving within 72 hours
- General: fever ≥39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours
- Receipt of live attenuated vaccine within 60 days or other vaccine within 30 days of enrolment
- Receipt of an experimental vaccines containing HIV antigens, Ad4 and MVA-C products at any time in the past
- Receipt of blood products or immunoglobin within 4 months of screening, or drugs that suppress the immune system, such as steroids (including inhaled steroids, excluding topical steroids unless applied to the upper arm), in the preceding 3 months
- Participating in another trial of a medicinal product, completed less than 30 days prior to enrolment
- HIV 1 or 2 positive or indeterminate on screening
- Positive for antibodies to hepatitis B surface antigen, hepatitis C antibody or serology indicating active syphilis requiring treatment
- Clinically significant positive reaction in antinuclear antibody screen or clinically significant immunoglobulin (IgA, IgG or IgM) values
- Grade 1 or above clinically significant routine laboratory parameters
- Unable to read and/or speak English to a fluency level adequate for the full comprehension of procedures required in participation and consent
- Women with a history of toxic shock syndrome
- Women using an intrauterine device for contraception (as incompatible with softcup sampling)
- Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
- Unlikely to comply with protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Group A
Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
|
Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
Other Names:
|
EXPERIMENTAL: Group B
Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
|
Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
Other Names:
Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
|
EXPERIMENTAL: Group C
Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
|
Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
Other Names:
Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
|
EXPERIMENTAL: Group D
Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo
|
Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
Other Names:
Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
|
ACTIVE_COMPARATOR: Group E
Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
|
Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
Other Names:
Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
|
EXPERIMENTAL: Group F
Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
|
Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
Other Names:
Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
|
EXPERIMENTAL: Group G
Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
|
Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
Other Names:
Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
|
EXPERIMENTAL: Group H
Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54
|
Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
Other Names:
Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mucosal antigen-specific antibodies measured by binding ELISA
Time Frame: At two weeks after the final immunisation
|
Frequency of mucosal binding antibodies to HIV CN54gp140 antigen
|
At two weeks after the final immunisation
|
Adverse events
Time Frame: Up to twenty-four weeks after the final immunisation
|
Frequency of adverse events
|
Up to twenty-four weeks after the final immunisation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum and mucosal antigen-specific antibodies measured by binding ELISA
Time Frame: Up to twenty-four weeks after the final immunisation
|
Frequency of serum and mucosal binding antibodies to HIV CN54gp140 antigen
|
Up to twenty-four weeks after the final immunisation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
Other Study ID Numbers
- Ad4HIV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
bioLytical LaboratoriesNot yet recruitingHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II Infection
-
Janssen R&D IrelandCompletedHuman Immunodeficiency Virus Type 1United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineTerminatedInfection, Human Immunodeficiency VirusSpain, France, Germany
Clinical Trials on CN54gp140/MPLA
-
ANRS, Emerging Infectious DiseasesUniversity College London Hospitals; Imperial College London; Medical Research... and other collaboratorsActive, not recruitingHealthy AdultsUnited Kingdom, Switzerland, France
-
MRC/UVRI and LSHTM Uganda Research UnitKing's College London; Karolinska Institutet; Gilead Sciences; Imperial College... and other collaboratorsEnrolling by invitation
-
Fundacion Clinic per a la Recerca BiomédicaPolymun Scientific GmbHRecruiting
-
Imperial College LondonWellcome Trust; National Institute for Health Research, United KingdomCompleted
-
Instituto de Investigação em ImunologiaButantan InstituteUnknownCancer. | Melanoma. | Ovarian Cancer. | Lung Cancer.Brazil
-
Alexandru EniuIuliu Hatieganu University of Medicine and PharmacyCompletedTo Determine the Prevalence, Penetrance of BRCA1 and BRCA2 Mutations in Romanian Womens With Breast or Ovarian CancerRomania
-
Imperial College LondonMedical Research CouncilCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedHIV-1-infectionNetherlands
-
St George's, University of LondonEuropean UnionCompletedHIV InfectionsUnited Kingdom
-
St George's, University of LondonBill and Melinda Gates Foundation; York HospitalsTerminatedHIV Infections | Acquired Immune Deficiency SyndromeUnited Kingdom